On March 14, 2023 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported publication of abstracts at the 2023 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (Press release, Ideaya Biosciences, MAR 14, 2023, View Source [SID1234628715]). IDEAYA will present data for its potential first-in-class synthetic lethality programs IDE397, a Phase 1/2 methionine adenosyltransferase 2a (MAT2A) inhibitor, IDE161, a Phase 1/2 poly (ADP-ribose) glycohydrolase (PARG) inhibitor, and Werner Helicase, for which a development candidate is targeted in 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstracts are available online at View Source in advance of the 2023 Annual Meeting of AACR (Free AACR Whitepaper), which will be held April 14-19, 2021. The posters will be available online at View Source following the poster presentations. These data will be presented by IDEAYA in collaboration with Amgen (IDE397) and GSK (IDE397, Werner Helicase).
Abstract 1644: "Dual inhibition of MAT2A and PRMT5 delivers synergistic anti-tumor responses in preclinical models of MTAP-deleted cancer" (Fischer, M. et al.)
Date/Time: Monday April 17, 2023 at 9:00 am – 12:30 pm ET
Session: Experimental and Molecular Therapeutics, Novel Antitumor Agents 4
Location: Poster Section 18, Poster Board 1
Presenters: IDEAYA, Amgen
Abstract 1637: "MAT2A inhibition in MTAP-/- tumors confers mechanistic vulnerabilities to multiple clinically actionable synthetic lethal drug combinations" (Gerrick, K. et al.)
Date/Time: Monday April 17, 2023 at 9:00 am – 12:30 pm ET
Session: Experimental and Molecular Therapeutics, Novel Antitumor Agents 3
Location: Poster Section 17, Poster Board 27
Presenters: IDEAYA, GSK
Abstract 6093: "IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets Homologous-Recombination-Deficient and PARP inhibitor resistant breast and ovarian tumors" (Abed, M. et al.)
Date/Time: Wednesday April 19, 2023 at 9:00 am – 12:30 pm ET
Session: Molecular/Cellular Biology and Genetics, Targeting DNA Damage Response and Novel Pathways
Location: Poster Section 13, Poster Board 1
Presenters: IDEAYA
Abstract 1628: "A small-molecule inhibitor of WRN selectively kills MSI-H cancer cells and phenocopies WRN genetic defects" (Rao, Y. et al.)
Date/Time: Monday April 17, 2023 at 9:00 am – 12:30 pm ET
Session: Experimental and Molecular Therapeutics, Novel Antitumor Agents 3
Location: Poster Section 17, Poster Board 18
Presenters: IDEAYA, GSK
"We are excited to present foundational preclinical data supporting our clinical-stage IDE397 and IDE161 programs and our preclinical Werner Helicase program. These data include fundamental mechanistic, biological and pharmacological insights which inform our ongoing or future clinical development plans for these programs," said Dr. Michael White, Chief Scientific Officer and Head of Research at IDEAYA Biosciences.
IDEAYA is clinically evaluating IDE397, a potential first-in-class small molecule inhibitor targeting MAT2A, in a Phase 1/2 clinical trial for patients having tumors harboring MTAP deletion. The IDE397 clinical development strategy includes ongoing IDEAYA-sponsored evaluation as monotherapy in select indications and planned Amgen-sponsored evaluation in combination with AMG 193, the Amgen investigational MTA-cooperative PRMT5 inhibitor, pursuant to a Clinical Trial Collaboration and Supply Agreement. IDEAYA owns all commercial rights to IDE397 and its MAT2A program.
IDEAYA is also clinically evaluating IDE161, a potential first-in-class PARG inhibitor, in a Phase 1/2 clinical trial for patients having tumors with HRD, including in BRCA1/2-mutant, ER+ / Her2- breast cancer, which represents approximately 10% to 14% of breast cancer. IDEAYA plans to initiate dosing of a first patient in the Phase 1 dose escalation study in the first quarter of 2023. IDEAYA owns or controls all commercial rights to IDE161 and its PARG program, subject to certain economic obligations under an exclusive, worldwide license with Cancer Research UK / University of Manchester.
IDEAYA is, in collaboration with GSK, preclinically advancing its Werner Helicase inhibitors for tumors with high microsatellite instability (MSI), with development candidate selection targeted in 2023. IDEAYA is eligible to receive future development and regulatory milestones, including up to $10 million aggregate through IND effectiveness – $3 million in connection with IND-enabling studies and an additional $7 million through IND effectiveness. Following selection of a development candidate, GSK will lead clinical development for the Werner Helicase program.